{"schemaVersion":"peptidescanner-peptide-evidence-feed/v1","canonicalUrl":"https://peptidescanner.com/feeds/peptides/nafarelin.json","peptide":{"slug":"nafarelin","name":"Nafarelin","url":"https://peptidescanner.com/peptides/nafarelin/"},"release":{"label":"Beta · 17 Nov 2026","reviewedAt":"2026-11-17"},"entryCount":28,"entries":[{"objectId":"story:clinicaltrials-gov-nct00034047-nafarelin:v1","state":"current","stateChangedAt":"2026-11-16","title":"ClinicalTrials.gov record NCT00034047","domain":"Clinical trials","dateInSource":"2008-01-25","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/clinicaltrials-gov-nct00034047-nafarelin/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#clinicaltrials-gov-nct00034047-nafarelin-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.md#clinicaltrials-gov-nct00034047-nafarelin-v1","contentSha256":"1540fe1bf5437eab6bc27a11b99a9b4aa8eb47d21b2c5c9c1d146fafb72da52a"},{"objectId":"story:clinicaltrials-gov-nct02865681-nafarelin:v1","state":"current","stateChangedAt":"2026-11-16","title":"ClinicalTrials.gov record NCT02865681","domain":"Clinical trials","dateInSource":"2019-03-19","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/clinicaltrials-gov-nct02865681-nafarelin/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#clinicaltrials-gov-nct02865681-nafarelin-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.md#clinicaltrials-gov-nct02865681-nafarelin-v1","contentSha256":"2355ab0dfa72739caacfbc8b4f49325568fee9a297ab4186b5b544c8ae0127df"},{"objectId":"story:fda-drugs-nda019886:v1","state":"current","stateChangedAt":"2026-11-16","title":"Drugs@FDA application NDA019886","domain":"Regulatory","dateInSource":"1990-02-13","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/fda-drugs-nda019886/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#fda-drugs-nda019886-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.md#fda-drugs-nda019886-v1","contentSha256":"579d6b1a17863330d09b060d64c2062921df064e58d38199f927b323aab75097"},{"objectId":"story:pubmed-pmid-10900582-nafarelin:v1","state":"current","stateChangedAt":"2026-11-16","title":"Clinical use of nafarelin in the treatment of leiomyomas. A review of the literature.","domain":"Literature metadata","dateInSource":"2013-11-21","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-10900582-nafarelin/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-10900582-nafarelin-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.md#pubmed-pmid-10900582-nafarelin-v1","contentSha256":"fe4a7e671bccdcde5a47e5d12e498c6c7d3827d1391704f1c28b9bb689ba8d9c"},{"objectId":"story:pubmed-pmid-11495415-nafarelin:v1","state":"current","stateChangedAt":"2026-11-16","title":"Ovarian hyperstimulation after the sole use of a gonadotrophin-releasing hormone agonist (Nafarelin) as a complication of in vitro fertilisation treatment.","domain":"Literature metadata","dateInSource":"2019-05-15","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-11495415-nafarelin/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-11495415-nafarelin-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.md#pubmed-pmid-11495415-nafarelin-v1","contentSha256":"389e522598fc5ea0f626e531ec94cd21089a497e62e658a078cbdfad3e395217"},{"objectId":"story:pubmed-pmid-11526758-nafarelin:v1","state":"current","stateChangedAt":"2026-11-16","title":"[Nafarelin acetate (Synarel) and thermocoagulation in the treatment of endometriosis].","domain":"Literature metadata","dateInSource":"2017-03-03","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-11526758-nafarelin/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-11526758-nafarelin-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.md#pubmed-pmid-11526758-nafarelin-v1","contentSha256":"00b231c31b46174514333c3dde01605bc336a5cc0971f0789ad8965dd430978a"},{"objectId":"story:pubmed-pmid-1531576-nafarelin:v1","state":"current","stateChangedAt":"2026-11-16","title":"Nafarelin in the management of endometriosis: quality of life assessment.","domain":"Literature metadata","dateInSource":"2019-06-15","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-1531576-nafarelin/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-1531576-nafarelin-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.md#pubmed-pmid-1531576-nafarelin-v1","contentSha256":"a8eb4fdea1df1c016c203d38fa7063ce0a82ed3c7ec20c3dacf81b3a2db25b7a"},{"objectId":"story:pubmed-pmid-1533376-nafarelin:v1","state":"current","stateChangedAt":"2026-11-16","title":"On the origin and significance of serum CA-125 concentrations in 97 patients with endometriosis before, during, and after buserelin acetate, nafarelin, or danazol.","domain":"Literature metadata","dateInSource":"2019-07-07","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-1533376-nafarelin/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-1533376-nafarelin-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.md#pubmed-pmid-1533376-nafarelin-v1","contentSha256":"3acfa84c850cdfb78e693b5f0534579e74ee7f44359b112a4861e4ee1db281b1"},{"objectId":"story:pubmed-pmid-18173008-nafarelin:v1","state":"current","stateChangedAt":"2026-11-16","title":"[Some possibilities for application of \"Pfizer\" medicines--Prostin 15m, Prostin E2, Prepidil gel, Dostinex, Synarel--in the obstetrician practice].","domain":"Literature metadata","dateInSource":"2018-12-01","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-18173008-nafarelin/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-18173008-nafarelin-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.md#pubmed-pmid-18173008-nafarelin-v1","contentSha256":"f2911e90db9b6e43b493fa5441fbc3e10cd39fc8b89ea5bccaea9a54b3dd15d2"},{"objectId":"story:pubmed-pmid-1834049-nafarelin:v1","state":"current","stateChangedAt":"2026-11-16","title":"A comparative treatment trial of endometriosis using the gonadotrophin-releasing hormone agonist, nafarelin, and the synthetic steroid, danazol.","domain":"Literature metadata","dateInSource":"2019-08-28","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-1834049-nafarelin/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-1834049-nafarelin-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.md#pubmed-pmid-1834049-nafarelin-v1","contentSha256":"39c6303cae08c6168730734ff82dfc5d68177bb464794416ea60f77738d570c6"},{"objectId":"story:pubmed-pmid-2028837-nafarelin:v1","state":"current","stateChangedAt":"2026-11-16","title":"Longitudinal precision of dual-energy x-ray absorptiometry in a multicenter study. The Nafarelin/Bone Study Group.","domain":"Literature metadata","dateInSource":"2007-11-15","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-2028837-nafarelin/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-2028837-nafarelin-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.md#pubmed-pmid-2028837-nafarelin-v1","contentSha256":"3f1f8bb87b6d5532f20de72089edb79c904f56b83eb9d0ed02ca548b0fb3b2c9"},{"objectId":"story:pubmed-pmid-2137620-nafarelin:v1","state":"current","stateChangedAt":"2026-11-16","title":"Nafarelin: a new medical therapy for endometriosis.","domain":"Literature metadata","dateInSource":"2013-11-21","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-2137620-nafarelin/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-2137620-nafarelin-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.md#pubmed-pmid-2137620-nafarelin-v1","contentSha256":"6159988db7bc43e14a802f77db7fdf5ce6e243cd68535e87a6b53217fb058ab9"},{"objectId":"story:pubmed-pmid-2137972-nafarelin:v1","state":"current","stateChangedAt":"2026-11-16","title":"Nafarelin in the treatment of pelvic pain caused by endometriosis.","domain":"Literature metadata","dateInSource":"2019-06-15","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-2137972-nafarelin/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-2137972-nafarelin-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.md#pubmed-pmid-2137972-nafarelin-v1","contentSha256":"f393a4fc2c59155e5d693b24ee024df9ba0aabb52ee1b6b59cfb6fc2e35720ff"},{"objectId":"story:pubmed-pmid-2137975-nafarelin:v1","state":"current","stateChangedAt":"2026-11-16","title":"Comparison of the pharmacology of nafarelin and danazol.","domain":"Literature metadata","dateInSource":"2019-06-15","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-2137975-nafarelin/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-2137975-nafarelin-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.md#pubmed-pmid-2137975-nafarelin-v1","contentSha256":"bb7d6375253f9fd19f3ec49e63f4e7c112eea9819d062c9c69f19a7f01c3aa31"},{"objectId":"story:pubmed-pmid-2137976-nafarelin:v1","state":"current","stateChangedAt":"2026-11-16","title":"Nafarelin versus danazol in the treatment of endometriosis.","domain":"Literature metadata","dateInSource":"2019-06-15","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-2137976-nafarelin/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-2137976-nafarelin-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.md#pubmed-pmid-2137976-nafarelin-v1","contentSha256":"3706569f52d1d7cfe8d13811cc8b185609b0dcfc8e7b8c67b5e5659278b2d723"},{"objectId":"story:pubmed-pmid-2140996-nafarelin:v1","state":"current","stateChangedAt":"2026-11-16","title":"A comparison of nafarelin acetate and danazol in the treatment of endometriosis.","domain":"Literature metadata","dateInSource":"2019-07-07","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-2140996-nafarelin/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-2140996-nafarelin-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.md#pubmed-pmid-2140996-nafarelin-v1","contentSha256":"ec2e3137c8c1ec6b5319642d9b178cd521e2bf08270b41e359b84f6dfb2bbeda"},{"objectId":"story:pubmed-pmid-2533526-nafarelin:v1","state":"current","stateChangedAt":"2026-11-16","title":"An attempt to alter the pathophysiology of polycystic ovary syndrome using a gonadotrophin hormone releasing hormone agonist--Nafarelin.","domain":"Literature metadata","dateInSource":"2026-11-09","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-2533526-nafarelin/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-2533526-nafarelin-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.md#pubmed-pmid-2533526-nafarelin-v1","contentSha256":"e867ce7d27fb56ecff84f34c7652b83d56d5762c9af6a96721911353897f5f23"},{"objectId":"story:pubmed-pmid-2533616-nafarelin:v1","state":"current","stateChangedAt":"2026-11-16","title":"Role of nafarelin in the management of endometriosis.","domain":"Literature metadata","dateInSource":"2013-11-21","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-2533616-nafarelin/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-2533616-nafarelin-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.md#pubmed-pmid-2533616-nafarelin-v1","contentSha256":"39dd14f4ee11e31b228f5a3fe8bfff9a154aa56fb65382354192abc8cc0ce393"},{"objectId":"story:pubmed-pmid-2533617-nafarelin:v1","state":"current","stateChangedAt":"2026-11-16","title":"Clinical experience treating endometriosis with nafarelin.","domain":"Literature metadata","dateInSource":"2013-11-21","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-2533617-nafarelin/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-2533617-nafarelin-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.md#pubmed-pmid-2533617-nafarelin-v1","contentSha256":"b4a8f35e1016f906d9de20eb939ad461a6c8ab6cdd0709ef07b1bf4841cc0c49"},{"objectId":"story:pubmed-pmid-2535115-nafarelin:v1","state":"current","stateChangedAt":"2026-11-16","title":"Experience in the use of nafarelin for treatment of benign breast disease.","domain":"Literature metadata","dateInSource":"2013-11-21","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-2535115-nafarelin/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-2535115-nafarelin-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.md#pubmed-pmid-2535115-nafarelin-v1","contentSha256":"210becef3946044082ed95e16e9c91eb80dc8fb9af68bbdb510d4e1aeca5580c"},{"objectId":"story:pubmed-pmid-2970910-nafarelin:v1","state":"current","stateChangedAt":"2026-11-16","title":"Absorption and metabolism of nafarelin, a potent agonist of gonadotropin-releasing hormone.","domain":"Literature metadata","dateInSource":"2019-05-10","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-2970910-nafarelin/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-2970910-nafarelin-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.md#pubmed-pmid-2970910-nafarelin-v1","contentSha256":"834d0165d42d8d867a38068bf0bdc1408a93082cf51446f6419aefeea3f58031"},{"objectId":"story:pubmed-pmid-7473446-nafarelin:v1","state":"current","stateChangedAt":"2026-11-16","title":"Endometriosis with a pleural effusion and ascites. Report of a case treated with nafarelin acetate.","domain":"Literature metadata","dateInSource":"2016-11-23","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-7473446-nafarelin/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-7473446-nafarelin-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.md#pubmed-pmid-7473446-nafarelin-v1","contentSha256":"f43d3052cfe5837e1b8f71c83a7078ff8a41c763ba9aac8698dbec3e26d73b22"},{"objectId":"story:pubmed-pmid-7485786-nafarelin:v1","state":"current","stateChangedAt":"2026-11-16","title":"[The use of Synarel (nafarelin acetate--spray) in gynecology].","domain":"Literature metadata","dateInSource":"2017-11-16","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-7485786-nafarelin/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-7485786-nafarelin-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.md#pubmed-pmid-7485786-nafarelin-v1","contentSha256":"aad6e03112fa5653787d089690c51695adff9331ea5611305248e10950cd33bf"},{"objectId":"story:pubmed-pmid-8569395-nafarelin:v1","state":"current","stateChangedAt":"2026-11-16","title":"Severe hyperkalaemia with nafarelin.","domain":"Literature metadata","dateInSource":"2019-06-11","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-8569395-nafarelin/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-8569395-nafarelin-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.md#pubmed-pmid-8569395-nafarelin-v1","contentSha256":"704331c6197d1daa4124bc3745b53b1c67aa7459174bf37de3d3d868bc4a96cd"},{"objectId":"story:pubmed-pmid-8860440-nafarelin:v1","state":"current","stateChangedAt":"2026-11-16","title":"Iontophoresis of nafarelin across human skin in vitro.","domain":"Literature metadata","dateInSource":"2019-08-18","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-8860440-nafarelin/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-8860440-nafarelin-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.md#pubmed-pmid-8860440-nafarelin-v1","contentSha256":"a078110b65781576c2031867f0741e3d1cd1844d7083a0c727aa9390a2be675b"},{"objectId":"story:pubmed-pmid-9209899-nafarelin:v1","state":"current","stateChangedAt":"2026-11-16","title":"A double-blind randomized study of the treatment of endometriosis with nafarelin or nafarelin plus norethisterone.","domain":"Literature metadata","dateInSource":"2019-11-02","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-9209899-nafarelin/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-9209899-nafarelin-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.md#pubmed-pmid-9209899-nafarelin-v1","contentSha256":"4c287e094044258478ff754c474f06c89407437d8f05245b1d3736128a0d5a73"},{"objectId":"story:pubmed-pmid-9389816-nafarelin:v1","state":"current","stateChangedAt":"2026-11-16","title":"Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis.","domain":"Literature metadata","dateInSource":"2019-07-07","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-9389816-nafarelin/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-9389816-nafarelin-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.md#pubmed-pmid-9389816-nafarelin-v1","contentSha256":"c145acb1fe493ce3e5bcbd68d44b09a5a5c4c567283ef6d9d3a50b12697494b2"},{"objectId":"story:pubmed-pmid-9720832-nafarelin:v1","state":"current","stateChangedAt":"2026-11-16","title":"Pre or post-operative medical treatment with nafarelin in stage III-IV endometriosis: a French multicenter study.","domain":"Literature metadata","dateInSource":"2019-08-16","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-9720832-nafarelin/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-9720832-nafarelin-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/nafarelin.md#pubmed-pmid-9720832-nafarelin-v1","contentSha256":"fd8f5333e51018312e161e21b6008f43957ffa7e433ca55fbed0cfa98463fbe2"}]}
